Research & Development

Biopharmaceutical firm UCB to invest £1bn in UK for research and development

Global biopharmaceutical company UCB is investing around £1bn in the UK for research and development, supporting the country’s life sciences sector.

DeepMind’s AlphaFold uses AI technology to predict protein shapes

Alphabet-owned DeepMind has claimed that research powered by artificial intelligence (AI) can help to predict the 3D structure of a protein on just its genetic sequence.

TRIGR Therapeutics, ABL Bio sign license deal for bispecific antibody candidate

TRIGR Therapeutics has expanded bispecific immuno-oncology pipeline with exclusive global license of clinical stage, dual angiogenesis inhibitor from ABL Bio.

GSK to buy oncology-focused biopharmaceutical firm Tesaro for $5.1bn

British drugmaker GlaxoSmithKline (GSK) has agreed to acquire US-based oncology-focused biopharmaceutical firm, Tesaro, for around £4bn ($5.1bn).

Biopharmaceutical firm Aprea Therapeutics raises €50m in financing

Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.

WuXi, ABL Bio to collaborate on multiple bispecific antibodies

WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.

AbCellera, Autolus partner on antibody discovery project

AbCellera, a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies, has collaborated with clinical stage biopharmaceutical company Autolus Therapeutics on antibody discovery project.

HOOKIPA, DarwinHealth to collaborate on immunotherapies development

HOOKIPA Pharma has signed a research collaboration and license agreement with DarwinHealth to develop immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.

BeiGene acquires rights to Zymeworks’ ZW25 and ZW49 bispecific candidates in Asia-Pacific

Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.